167 related articles for article (PubMed ID: 38327117)
1. In silico trial for the assessment of givinostat dose adjustment rules based on the management of key hematological parameters in polycythemia vera patients.
Tosca EM; De Carlo A; Bartolucci R; Fiorentini F; Di Tollo S; Caserini M; Rocchetti M; Bettica P; Magni P
CPT Pharmacometrics Syst Pharmacol; 2024 Mar; 13(3):359-373. PubMed ID: 38327117
[TBL] [Abstract][Full Text] [Related]
2. Givinostat: an emerging treatment for polycythemia vera.
Chifotides HT; Bose P; Verstovsek S
Expert Opin Investig Drugs; 2020 Jun; 29(6):525-536. PubMed ID: 32693648
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program.
Rambaldi A; Iurlo A; Vannucchi AM; Martino B; Guarini A; Ruggeri M; von Bubnoff N; De Muro M; McMullin MF; Luciani S; Martinelli V; Nogai A; Rosti V; Ricco A; Bettica P; Manzoni S; Di Tollo S
Blood Cancer J; 2021 Mar; 11(3):53. PubMed ID: 33677466
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy.
Finazzi G; Vannucchi AM; Martinelli V; Ruggeri M; Nobile F; Specchia G; Pogliani EM; Olimpieri OM; Fioritoni G; Musolino C; Cilloni D; Sivera P; Barosi G; Finazzi MC; Tollo SD; Demuth T; Barbui T; Rambaldi A
Br J Haematol; 2013 Jun; 161(5):688-694. PubMed ID: 23573950
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic-pharmacodynamic analysis of givinostat.
Fiorentini F; Germani M; Del Bene F; Pellizzoni C; Cazzaniga S; Rocchetti M; Bettica P
Expert Opin Drug Metab Toxicol; 2023 Apr; 19(4):229-238. PubMed ID: 37306105
[TBL] [Abstract][Full Text] [Related]
6. A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms.
Rambaldi A; Dellacasa CM; Finazzi G; Carobbio A; Ferrari ML; Guglielmelli P; Gattoni E; Salmoiraghi S; Finazzi MC; Di Tollo S; D'Urzo C; Vannucchi AM; Barosi G; Barbui T
Br J Haematol; 2010 Aug; 150(4):446-55. PubMed ID: 20560970
[TBL] [Abstract][Full Text] [Related]
7. Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2(V617F) myeloproliferative neoplasm patients.
Amaru Calzada A; Pedrini O; Finazzi G; Leoni F; Mascagni P; Introna M; Rambaldi A; Golay J;
Exp Hematol; 2013 Mar; 41(3):253-60.e2. PubMed ID: 23111067
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera.
Jin J; Qin A; Zhang L; Shen W; Wang W; Zhang J; Li Y; Wu D; Xiao Z
Future Oncol; 2023 Apr; 19(11):753-761. PubMed ID: 37129584
[TBL] [Abstract][Full Text] [Related]
9. Platelet thromboxane inhibition by low-dose aspirin in polycythemia vera: Ex vivo and in vivo measurements and in silico simulation.
Petrucci G; Giaretta A; Ranalli P; Cavalca V; Dragani A; Porro B; Hatem D; Habib A; Tremoli E; Patrono C; Rocca B
Clin Transl Sci; 2022 Dec; 15(12):2958-2970. PubMed ID: 36200184
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy and Safety of Ruxolitinib in Polycythemia Vera].
Chang L; Duan MH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1515-1518. PubMed ID: 36208258
[TBL] [Abstract][Full Text] [Related]
11. Hematocrit, White Blood Cells, and Thrombotic Events in the Veteran Population With Polycythemia Vera.
Tashi T
Fed Pract; 2022 May; 39(Suppl 2):S43-S46. PubMed ID: 35929004
[TBL] [Abstract][Full Text] [Related]
12. The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study.
Mascarenhas J; Passamonti F; Burbury K; El-Galaly TC; Gerds A; Gupta V; Higgins B; Wonde K; Jamois C; Kovic B; Huw LY; Katakam S; Maffioli M; Mesa R; Palmer J; Bellini M; Ross DM; Vannucchi AM; Yacoub A
Blood Adv; 2022 Feb; 6(4):1162-1174. PubMed ID: 34933330
[TBL] [Abstract][Full Text] [Related]
13. Novel Therapies in Polycythemia Vera.
Tremblay D; Mascarenhas J
Curr Hematol Malig Rep; 2020 Apr; 15(2):133-140. PubMed ID: 32034662
[TBL] [Abstract][Full Text] [Related]
14. Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera.
Kremyanskaya M; Kuykendall AT; Pemmaraju N; Ritchie EK; Gotlib J; Gerds A; Palmer J; Pettit K; Nath UK; Yacoub A; Molina A; Saks SR; Modi NB; Valone FH; Khanna S; Gupta S; Verstovsek S; Ginzburg YZ; Hoffman R;
N Engl J Med; 2024 Feb; 390(8):723-735. PubMed ID: 38381675
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study.
Rambaldi A; Iurlo A; Vannucchi AM; Noble R; von Bubnoff N; Guarini A; Martino B; Pezzutto A; Carli G; De Muro M; Luciani S; McMullin MF; Cambier N; Marolleau JP; Mesa RA; Tibes R; Pancrazzi A; Gesullo F; Bettica P; Manzoni S; Di Tollo S
Leukemia; 2020 Aug; 34(8):2234-2237. PubMed ID: 32047238
[No Abstract] [Full Text] [Related]
16. Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL.
Gerds AT; Mesa R; Burke JM; Grunwald MR; Stein BL; Squier P; Yu J; Hamer-Maansson JE; Oh ST
Blood; 2024 Apr; 143(16):1646-1655. PubMed ID: 38142448
[TBL] [Abstract][Full Text] [Related]
17. Polycythemia Vera (PV): Update on Emerging Treatment Options.
Benevolo G; Vassallo F; Urbino I; Giai V
Ther Clin Risk Manag; 2021; 17():209-221. PubMed ID: 33758507
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Mercuri E; Vilchez JJ; Boespflug-Tanguy O; Zaidman CM; Mah JK; Goemans N; Müller-Felber W; Niks EH; Schara-Schmidt U; Bertini E; Comi GP; Mathews KD; Servais L; Vandenborne K; Johannsen J; Messina S; Spinty S; McAdam L; Selby K; Byrne B; Laverty CG; Carroll K; Zardi G; Cazzaniga S; Coceani N; Bettica P; McDonald CM;
Lancet Neurol; 2024 Apr; 23(4):393-403. PubMed ID: 38508835
[TBL] [Abstract][Full Text] [Related]
19. Novel and emerging therapies for the treatment of polycythemia vera.
Verstovsek S; Komrokji RS
Expert Rev Hematol; 2015 Feb; 8(1):101-13. PubMed ID: 25353086
[TBL] [Abstract][Full Text] [Related]
20. A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.
Illés Á; Pinczés LI; Egyed M
Expert Opin Drug Metab Toxicol; 2021 Jan; 17(1):3-7. PubMed ID: 33118413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
